Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study

Cancer Investigation
Andrew H KoMargaret A Tempero

Abstract

No therapeutic standard of care exists for patients with advanced pancreatic cancer who progress following first-line treatment with a gemcitabine-based regimen. There is evidence of synergistic activity between docetaxel and irinotecan, and the combination of these two agents has shown promising efficacy in the first-line setting for advanced pancreatic cancer. We, therefore, evaluated this regimen in patients with gemcitabine-refractory disease. Eligible patients with metastatic pancreatic adenocarcinoma were required to have an elevated serum CA19-9 (> 2x ULN) and exposure to one or two prior chemotherapy regimens, including one gemcitabine-based. Treatment consisted of docetaxel 65 mg/m2 and irinotecan 160 mg/m2, both administered every 21 days. Serum CA19-9 levels were measured at the start of each treatment cycle and CT scans performed after every two cycles. Fourteen patients were enrolled before the study was closed due to excess toxicity. The most common grade 3/4 toxicities included neutropenia/leukopenia, nausea and vomiting, and diarrhea. Fully half of patients received only 1 treatment cycle, with a median time to treatment failure of 36 days. No objective responses were observed, although 3 patients had stable dis...Continue Reading

References

Jun 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H A BurrisD D Von Hoff
Mar 1, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A A AdjeiC Erlichman
Jul 8, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P RougierJ P Armand
Aug 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N MasudaM Fukuoka
Oct 14, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C CouteauJ P Armand
Jul 26, 2002·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·A FontA Abad
Mar 29, 2005·The Oncologist·Howard A BurrisArthur Staddon
Dec 14, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew H KoMargaret A Tempero
Jul 21, 2006·Cancer Chemotherapy and Pharmacology·Hideki UenoSoh Saitoh
Jan 24, 2007·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun

❮ Previous
Next ❯

Citations

Aug 19, 2011·Cancer Chemotherapy and Pharmacology·Hassan K DakikDavid R Fogelman
Mar 2, 2010·Japanese Journal of Clinical Oncology·Akiko TodakaHideharu Tomita
Mar 1, 2010·Therapeutic Advances in Medical Oncology·Ben Lawrence, Michael Findlay
Sep 13, 2012·World Journal of Gastroenterology : WJG·Carmen BelliMichele Reni
Sep 13, 2012·World Journal of Gastroenterology : WJG·Cindy NeuzilletPascal Hammel
Mar 8, 2014·World Journal of Gastroenterology : WJG·Evan J Walker, Andrew H Ko
Feb 9, 2013·Seminars in Oncology·Matthew H Kulke
May 14, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Uwe PelzerHelmut Oettle
Apr 7, 2010·The Surgical Clinics of North America·Sharmila P Mehta
Oct 21, 2015·Critical Reviews in Oncology/hematology·Adnan M NagrialDesmond Yip
Dec 19, 2012·International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·Katharina Elisabeth Tschoep-LechnerRolf-Dieter Issels
Jul 16, 2008·Radiologic Clinics of North America·Andrei IagaruSanjiv Sam Gambhir
Apr 27, 2011·The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi·Jeong Youp Park
Feb 5, 2010·Cancer Chemotherapy and Pharmacology·Andrew H KoMargaret A Tempero
Jan 28, 2014·Anti-cancer Drugs·E Gabriela Chiorean, Daniel D Von Hoff
Mar 6, 2009·Current Opinion in Supportive and Palliative Care

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.